Analyzing DGX's Price Surge – Will Market Sentiment Keep It Afloat?

Quest Diagnostics shares rose 3.1% this morning to a price of $140.9. The stock is still trading within range of its average target price of $147.46, and over the last 52 weeks, it has recorded a 1.4% performance. Analysts have given the Large-Cap Medical Specialities stock target prices ranging from $136.0 to $160.0 dollars per share, with an average rating of buy.

Quest Diagnostics's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.4%. The stock's short ratio is 2.75. The company's insiders own 0.44% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 92.9%. In conclusion, we believe there is mixed market sentiment regarding Quest Diagnostics.

Institutions Invested in Quest Diagnostics

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 13% 13,921,955 $1,961,603,374
2024-03-31 Blackrock Inc. 10% 10,700,573 $1,507,710,670
2024-03-31 State Street Corporation 5% 5,199,194 $732,566,402
2024-03-31 Victory Capital Management Inc. 4% 3,922,331 $552,656,413
2024-03-31 American Century Companies Inc 3% 3,873,742 $545,810,224
2024-03-31 Wellington Management Group, LLP 2% 2,612,769 $368,139,136
2024-03-31 Geode Capital Management, LLC 2% 2,533,572 $356,980,279
2024-03-31 Davis Selected Advisers, LP 2% 2,381,163 $335,505,852
2024-03-31 Grantham, Mayo, Van Otterloo & Co. LLC 2% 2,043,255 $287,894,617
2024-03-31 Dimensional Fund Advisors LP 2% 1,980,120 $278,998,895
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.